Evidence map›Paper›PMID 19840862›Full record

ArticleMetabolic engineering2010

Model-driven evaluation of the production potential for growth-coupled products of Escherichia coli.

Adam M Feist, Daniel C Zielinski, Jeffrey D Orth, Jan Schellenberger, Markus J Herrgard, Bernhard Ø Palsson

Abstract read
In one paragraph

Article in Metabolic engineering, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed.

  1. Metabolic growth-coupling strategies forMetabolic engineering communications · 2025
    Article
  2. Article
  3. Article
  4. Review
  5. Evaluation of Cell Responses ofMicroorganisms · 2023
    Article
  6. On the representativeness and stability of a set of EFMs.Bioinformatics (Oxford, England) · 2023
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. A Beginner's Guide to the COBRA Toolbox.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Adam M FeistDepartment of Bioengineering, University of California, 9500 Gilman Drive #0412, San Diego, La Jolla, CA 92093-0412, USA.
Daniel C Zielinski
Jeffrey D Orth
Jan Schellenberger
Markus J Herrgard
Bernhard Ø Palsson

Funding

GENOMICALLY BASED MODELS FOR ANTIBIOTIC DEVELOPMENTR01GM057089 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PALSSON, BERNHARD O · 1998 to 2021
$6.9M
NIGMS NIH HHS R01 GM057089NIGMS NIH HHS R01GM057089
6 · The paper itself

Abstract

Integrated approaches utilizing in silico analyses will be necessary to successfully advance the field of metabolic engineering. Here, we present an integrated approach through a systematic model-driven evaluation of the production potential for the bacterial production organism Escherichia coli to produce multiple native products from different representative feedstocks through coupling metabolite production to growth rate. Designs were examined for 11 unique central metabolism and amino acid targets from three different substrates under aerobic and anaerobic conditions. Optimal strain designs were reported for designs which possess maximum yield, substrate-specific productivity, and strength of growth-coupling for up to 10 reaction eliminations (knockouts). In total, growth-coupled designs could be identified for 36 out of the total 54 conditions tested, corresponding to eight out of the 11 targets. There were 17 different substrate/target pairs for which over 80% of the theoretical maximum potential could be achieved. The developed method introduces a new concept of objective function tilting for strain design. This study provides specific metabolic interventions (strain designs) for production strains that can be experimentally implemented, characterizes the potential for E. coli to produce native compounds, and outlines a strain design pipeline that can be utilized to design production strains for additional organisms.

Indexed as

Escherichia coliModels, BiologicalBacteriaBiological PhenomenaGrowthRisk Factors

Identifiers

PMID19840862
PMCPMC3125152

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.